Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate whether intramuscular injections of NL003 into the calf is safe and effective in the treatment of critical limb ischemia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)

NCT04274049

Arterial Occlusive Disease Ischemia Ulcers +1 more

COMPLETED PHASE3

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)

NCT04275323

Arterial Occlusive Disease Ischemia Ulcers +1 more

COMPLETED PHASE3

Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)

NCT07023965

Peripheral Arterial Disease(PAD) Arterial Occlusive Disease Arteriosclerosis Obliterans +4 more

ENROLLING_BY_INVITATION

VEGF Gene Transfer for Critical Limb Ischemia

NCT00304837

Critical Limb Ischemia Ischemia Leg Ulcer

COMPLETED PHASE1

Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia

NCT05498740

Peripheral Arterial Disease (PAD)

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Management of CLI process consumes a significant amount of healthcare resources,and the new therapeutic approaches are required.

Hepatocyte growth factor (HGF) has been shown to be a potent angiogenic growth factor stimulating the growth of endothelial cells and migration of vascular smooth muscle cells. Because of its pluripotent capabilities, increasing the availability of HGF in ischemic tissues to achieve therapeutic angiogenesis has been a growing area of research.

This study will use NL003, which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. As there are currently no approved drugs that can reverse CLI and as most patients have exhausted surgical and endovascular intervention options, inducing angiogenesis in the affected limb with NL003 may result in an increase in tissue perfusion, which, in turn improve wound healing, reduce pain and improve limb salvage rates.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Occlusive Disease Ulcers Ischemia Peripheral Vascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High Dose

Patients in this treatment group will receive 8mg NL003 respective in D0、14、28

Group Type EXPERIMENTAL

NL003

Intervention Type GENETIC

Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)

Middle Dose

Patients in this treatment group will receive 6mg NL003 respective in D0、14、28

Group Type EXPERIMENTAL

NL003

Intervention Type GENETIC

Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)

Low Dose

Patients in this treatment group will receive 4mg NL003 in D0、14、28

Group Type EXPERIMENTAL

NL003

Intervention Type GENETIC

Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)

Placebo

Patients in this group will receive normal saline respective in D0、14、18

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type OTHER

Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NL003

Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)

Intervention Type GENETIC

NL003

Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)

Intervention Type GENETIC

NL003

Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)

Intervention Type GENETIC

Normal Saline

Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HGF plasmid pCK-HGF-X7 HGF plasmid pCK-HGF-X7 HGF plasmid pCK-HGF-X7 Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, between 30 and 80years of age
* Diagnosis of critical limb ischemia(ASO、TAO、DAO)，Rutherford Class 4 or 5, including:

* A resting ankle systolic pressure of ≤ 70 mmHg in the affected limb; or
* A resting toe systolic pressure of ≤ 50 mmHg in the affected limb; or
* For patients in which measurement of ankle systolic pressure is not feasible , TcPO2 ≤ 30mmHg; Only unilateral affected limb receive treatment。
* Significant stenosis (≥ 75%) of one or more of the following arteries:

superficial femoral, popliteal as verified by angiography（DSA、CTA、MRA） within 12 months prior to enrollment

* Be willing to maintain current drug therapy for peripheral arterial disease throughout the course of the study
* Be willing to maintain ulcer treatment
* Be willing to infertility throughout the course of the study
* If the subject is of child-bearing potential, she must have a negative urine pregnancy test result prior to study enrollment
* Tumor screening result is no clinic meaning，including:
* Signing the informed consent document prior to being subjected to any study related procedures

Exclusion Criteria

* Subjects who have undergone a successful revascularization procedure or sympathectomy within 12 weeks prior to study entry.
* Acute advanced CLI
* Subjects that will require an amputation in the target leg within 4 weeks, or significant stenosis (≥ 75%) of Aortoiliac
* Subjects with evidence of active infection or deep ulceration exposing bone or tendon in the extremity planned for treatment
* Heart Failure with a NYHA classification of III or IV
* Stroke、myocardial infarction or unstable angina within last 3 months
* Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) \> 180 mmHg or diastolic BP (DBP) \> 110 mmHg
* Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination
* Can not correctly describe the symptoms and feeling
* Subjects with advanced liver disease including decompensated cirrhosis, jaundice, ascites or bleeding varices
* Subjects currently receiving immunosuppressive medications chemotherapy, or radiation therapy
* Positive HIV,active Hepatitis B(determined by HBsAb\\ HBcAb\\HBsAg) or C infection
* Specific laboratory values at Screening including: Hemoglobin \< 8.0 g/dL, WBC \< 3,000 cells per microliter, platelet count \<75,000/mm3, AST and/or ALT \> 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary
* Elevated PSA unless prostate cancer has been excluded
* Patients with a recent history (\< 5 years) of or new screening finding of malignant neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of recurrence); patients with family history of colon cancer in any first degree relative are excluded unless they have undergone a colonoscopy in the last 12 months with negative findings
* Subjects requiring \> 100 mg daily of acetylsalicylic acid,COX-2 inhibitor drug(s) or high dose steroids (excepting inhaled steroids)
* Subjects with any co- morbid conditions likely to interfere with assessment of safety or efficacy or with an estimated life expectancy of less than 12 months
* History of drug or alcohol abuse / dependence in the past 12 months
* Use of an investigational drug or treatment in past 3 months

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No